search
Back to results

Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients

Primary Purpose

Postoperative Pain

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Q8003 (morphine sulfate and oxycodone hydrochloride)
Morphine sulfate
Oxycodone HCl
Sponsored by
QRxPharma Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postoperative Pain focused on measuring Bunionectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient is male or female and at least 18 years of age.
  • Females must be non-pregnant, non-lactating, and practicing an acceptable method of birth control, or be surgically sterile or postmenopausal (amenorrhea for ≥ 12 months). Non-pregnancy will be confirmed by pregnancy tests conducted at Screening and Pre-treatment.
  • Patient is scheduled for bunionectomy surgery, meets the criteria of an ASA Class I to III, and is willing to stay in the study center for at least 48 hours from the initial dose of study medication post surgery.
  • To be randomized after surgery, the patient must report moderate to severe pain (a score of 2 or more on the 4 point Likert scale or 4 or more on the 11 point NPRS scale).
  • At least 40% of study subjects will be 60 years of age or older.

Exclusion Criteria:

  • In the opinion of the Investigator, has a history of pulmonary, cardiovascular (including uncontrolled hypertension), neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that would jeopardize the patient's well being by participation in this study or is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.
  • Used opiates continuously (including tramadol) for more than ten days in the past year.
  • Hypersensitivity or poor tolerance to acetaminophen.
  • Currently receiving any medications that are not at a stable dose (the same dose for > 2 months prior to date of surgery).
  • Was dosed with another investigational drug within 30 days prior to the Screening Visit or has previously received treatment with Q8003.
  • Current therapy with central nervous system depressant medications that might increase the risks of treatment with opioids (other than those used with surgical anesthesia).
  • Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).

Sites / Locations

  • Investigational site
  • Investigational site
  • Investigational site
  • Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Q8003 12 mg/8 mg

Morphine sulfate 24 mg

Oxycodone HCl 16 mg

Arm Description

Combination

Single component

Single component

Outcomes

Primary Outcome Measures

Differences in desaturation events per standardized time unit

Secondary Outcome Measures

Difference in efficacy between Q8003 and its components (morphine and oxycodone)
Changes from baseline in pain intensity
Differences in the absence of emesis without the use of an anti-emetic (emesis complete response)

Full Information

First Posted
January 18, 2011
Last Updated
May 15, 2012
Sponsor
QRxPharma Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01280331
Brief Title
Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients
Official Title
A Randomized, Double-Blind, Multi-Center, Repeat-Dose, Comparison of the Effects of Q8003 to the Morphine-Equivalent Doses of Oxycodone and of Morphine on the Opioid-Related Adverse Events of Moderate to Severe Nausea, Emesis, and Dizziness in Subjects With Acute Moderate-to-Severe Postoperative Pain Following Bunionectomy Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
April 2011 (Actual)
Study Completion Date
April 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
QRxPharma Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a randomized, double-blind, multicenter, repeat-dose study of fixed doses of Q8003 12 mg/8 mg given q6hr compared to morphine sulfate 24 mg and oxycodone hydrochloride 16 mg given q6hr for the management of acute moderate to severe postoperative pain for 48 hours following bunionectomy surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
Bunionectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
375 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Q8003 12 mg/8 mg
Arm Type
Experimental
Arm Description
Combination
Arm Title
Morphine sulfate 24 mg
Arm Type
Active Comparator
Arm Description
Single component
Arm Title
Oxycodone HCl 16 mg
Arm Type
Active Comparator
Arm Description
Single component
Intervention Type
Drug
Intervention Name(s)
Q8003 (morphine sulfate and oxycodone hydrochloride)
Intervention Description
Two Q8003 6 mg/4 mg IR Capsules q6h
Intervention Type
Drug
Intervention Name(s)
Morphine sulfate
Intervention Description
Two morphine sulfate 12 mg IR capsules q6h
Intervention Type
Drug
Intervention Name(s)
Oxycodone HCl
Intervention Description
Two oxycodone HCl 8 mg IR Capsules q6h
Primary Outcome Measure Information:
Title
Differences in desaturation events per standardized time unit
Time Frame
48 hours
Secondary Outcome Measure Information:
Title
Difference in efficacy between Q8003 and its components (morphine and oxycodone)
Description
Changes from baseline in pain intensity
Time Frame
48 hours
Title
Differences in the absence of emesis without the use of an anti-emetic (emesis complete response)
Time Frame
48 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is male or female and at least 18 years of age. Females must be non-pregnant, non-lactating, and practicing an acceptable method of birth control, or be surgically sterile or postmenopausal (amenorrhea for ≥ 12 months). Non-pregnancy will be confirmed by pregnancy tests conducted at Screening and Pre-treatment. Patient is scheduled for bunionectomy surgery, meets the criteria of an ASA Class I to III, and is willing to stay in the study center for at least 48 hours from the initial dose of study medication post surgery. To be randomized after surgery, the patient must report moderate to severe pain (a score of 2 or more on the 4 point Likert scale or 4 or more on the 11 point NPRS scale). At least 40% of study subjects will be 60 years of age or older. Exclusion Criteria: In the opinion of the Investigator, has a history of pulmonary, cardiovascular (including uncontrolled hypertension), neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that would jeopardize the patient's well being by participation in this study or is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments. Used opiates continuously (including tramadol) for more than ten days in the past year. Hypersensitivity or poor tolerance to acetaminophen. Currently receiving any medications that are not at a stable dose (the same dose for > 2 months prior to date of surgery). Was dosed with another investigational drug within 30 days prior to the Screening Visit or has previously received treatment with Q8003. Current therapy with central nervous system depressant medications that might increase the risks of treatment with opioids (other than those used with surgical anesthesia). Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patricia T. Richards, MD, Ph.D.
Organizational Affiliation
QRxPharma Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Investigational site
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Investigational site
City
Owings Mills
State/Province
Maryland
ZIP/Postal Code
21117
Country
United States
Facility Name
Investigational site
City
Pasadena
State/Province
Maryland
ZIP/Postal Code
21122
Country
United States
Facility Name
Investigational Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients

We'll reach out to this number within 24 hrs